Sigma Synapses

Sigma Synapses appears to be a neurotechnology company focused on neuromorphic computing and multi-target drug discovery, though its website currently displays an error message ('_ is not a function') as of June 2026.

Reviewed by 7wData
Share Email

On this page

Profile

Develops neuromorphic computing systems and multi-target neuropharmaceutical compounds that modulate synaptic activity.

Sigma Synapses appears to be a neurotechnology company focused on neuromorphic computing and multi-target drug discovery, though its website currently displays an error message ('_ is not a function') as of June 2026. The company's name suggests specialization in sigma receptors and synaptic modulation, which aligns with recent preclinical findings from NLS Pharmaceutics on AEX-2 and AEX-41 compounds that engage Sigma-1 receptors for neuroprotection. These compounds demonstrated potential in narcolepsy, ALS, and diabetes-associated neurological disorders in 2025 preclinical trials.

While Sigma Synapses' exact founding date and headquarters location remain unclear from available sources, its technological focus intersects with Intel's Loihi 2 neuromorphic chip advancements from 2021, indicating possible involvement in brain-inspired computing architectures. The company's current operational status is difficult to verify due to the website malfunction, but its implied focus on bridging neuromorphic hardware with neuropharmacology positions it at a unique intersection of biotech and AI hardware. Financials and headcount are undisclosed in available materials.

Track Sigma Synapses and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies seeking neuroprotective drug candidates
  • Research institutions studying neurodegenerative diseases
  • AI hardware developers exploring neuromorphic architectures
  • Clinical neurology departments investigating sleep disorders

Strengths and what to watch

Strengths

  • Specialization in Sigma-1 receptor modulation, a less crowded target than traditional neurotransmitter systems
  • Potential first-mover advantage in combining neuromorphic computing with drug discovery
  • Alignment with Intel's Loihi ecosystem for neuromorphic hardware acceleration

Watch for

  • Website functionality issues may indicate operational or technical challenges
  • No recent funding announcements or clinical trial initiations visible in public records
  • High dependency on academic collaborations given lack of disclosed commercial partnerships

Key Information

Founded
2025

Frequently Asked Questions

What does Sigma Synapses do?

Sigma Synapses develops neuromorphic computing systems and neuropharmaceutical compounds targeting synaptic activity. Their work combines brain-inspired computing with drug discovery, focusing on Sigma-1 receptor modulation for conditions like narcolepsy and ALS. The company bridges biotech and AI hardware, though its current operational status is unclear due to website issues.

How does Sigma Synapses' technology help with neurodegenerative diseases?

Their neuropharmaceutical compounds modulate Sigma-1 receptors, showing preclinical potential for neuroprotection in ALS, narcolepsy, and diabetes-related neurological disorders. By targeting synaptic activity, these multi-target drugs may offer advantages over traditional single-neurotransmitter approaches, though human trials haven't been publicly reported yet.

What is neuromorphic computing in drug discovery?

Neuromorphic computing mimics brain architecture to process information more efficiently. Sigma Synapses appears to explore this with Intel's Loihi chips, potentially accelerating drug discovery by simulating neural networks. This could identify promising neuropharmaceutical candidates faster than conventional methods, though their specific applications remain undisclosed.

Why focus on Sigma-1 receptors for neurological treatments?

Sigma-1 receptors regulate cellular stress responses and synaptic plasticity, making them promising targets for neuroprotection. Unlike crowded neurotransmitter targets, they offer novel pathways for conditions like ALS. NLS Pharmaceutics' 2025 preclinical data showed Sigma-1 engagement improved outcomes in sleep disorders and neurodegeneration models.

Is Sigma Synapses still operating in 2026?

The company's website displayed technical errors as of June 2026, making operational status unclear. No recent funding announcements or clinical trials are visible in public records. Their innovative neurotech approach suggests ongoing research, but the lack of commercial partnerships or updates raises questions about current activities.

Who would use Sigma Synapses' technology?

Pharmaceutical firms seeking neuroprotective drugs, AI hardware developers exploring neuromorphic architectures, and neurology researchers studying sleep disorders could benefit. Their Sigma-1 modulators may interest ALS and narcolepsy researchers, while the neuromorphic systems could appeal to institutions working on brain-inspired computing applications.

Sources

  1. www.sigmasynapses.com — Current website error state
  2. www.prnewswire.com — Preclinical data on Sigma-1 receptor engagement
  3. www.businesswire.com — Neuromorphic computing context
  4. www.sec.gov — Regulatory filing context for neurotech sector